MTAR Technologies Ltd
MTARTECHMTAR Technologies Ltd's price has outrun its earnings. +301.0% in a year against EPS +77.8% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +301.0% in a year while annual EPS moved +77.8% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (43 weeks in) while the P/E sits at the 74th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +354.5% year on year, and 175% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
MTAR Technologies Ltd trades at ₹5,726, in a confirmed uptrend and 43 weeks into that stage. That is +19.0% against its own 200-day average. It sits at 60% of a 52-week range of ₹1,798 to ₹8,375. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (5 weeks and counting).
Today the stock is in a confirmed uptrend — week 43 of stage 2, confirmed. At ₹5,726 it trades +19.0% versus its 200-day average and sits at 60% of its 52-week range (₹1,798–₹8,375).
Against the market, two honest reads. Cumulative: over the last 5.4 years the stock moved +491% while the NIFTY 500 moved +92% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (5 weeks and counting; last ahead the week of 2026-07-01) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
MTAR Technologies Ltd trades at 129.0× P/E, at the pricey end of its own range (74th percentile). Its long-run median P/E is 91.7×, measured across 5.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 129.0× is at the pricey end of its own range (74th percentile), against a long-run median of 91.7× measured over 5.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +77.8% against a +301.0% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +31.7%/yr price move, ~+24.2%/yr came from earnings growth and ~+7.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
MTAR Technologies Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 7 quarters ago at −62.7% and has held its recovery at +121.7%, ROCE lifting at 16.9%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +29.6% | +15.1% | +28.9% | +26.9% |
| Profit | +77.4% | −3.0% | +15.4% | — |
| EPS | +77.8% | −3.1% | +15.3% | +86.5% |
| Share price | +301.0% | +39.1% | +31.7% | — |
4-Factor Sector Score
63.2/100 — rank 5 of 24 in Aerospace & Defence - Equipments · 90% evidence confidence
MTAR Technologies Ltd scores 63.2 out of 100 against the 24 companies it is compared with in Aerospace & Defence - Equipments, ranking 5. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 30.7 + 13.9 + 6.3 + 12.3 = 63.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
MTAR Technologies Ltd reported ₹361 Cr of revenue in the Jun 26 quarter, +129.9% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 26.9% a year. The last full year, FY26, came in at ₹876 Cr. The last four reported quarters add to ₹1,081 Cr.
FY26 revenue came in at ₹876 Cr (+29.6% on the year), capping 10 years at 26.9% compound. The latest quarter (Jun 26) printed ₹361 Cr, +129.9% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +57.1% growth against the decade's 26.9% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +53.6% over the last 4 quarters against +39.4%/yr over the last 8 — accelerating; TTM profit +121.7% vs +84.7%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
MTAR Technologies Ltd's operating margin is 24.0% in the Jun 26 quarter, +6.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −12.0% to 34.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 24.0%, +6.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −12.0%–34.0%.
Why the margin moved: operating margin went +5.4 pp year on year while gross margin went −8.7 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
MTAR Technologies Ltd earned ₹50.0 Cr of net profit in the Jun 26 quarter, +354.5% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹94.0 Cr. That is 13.9% of the quarter's revenue. The same quarter a year earlier earned ₹11.0 Cr.
Jun 26 profit was ₹50.0 Cr, +354.5% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹94.0 Cr (+77.4%).
Why profit moved: revenue contributed +129.9% and the margin +6.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +152.2% vs revenue +57.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 175% of MTAR Technologies Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹197 Cr of operating cash against ₹94.0 Cr of profit. After ₹91.0 Cr of capital spending, ₹106 Cr was left as free cash.
FY26: operating cash of ₹197 Cr against reported profit of ₹94.0 Cr, leaving free cash of ₹106 Cr after ₹91.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 175% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 175%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 3.1× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
MTAR Technologies Ltd's cash conversion cycle runs 419 days in FY26, down from 423 days in FY21. Capital spending ran ₹283 Cr over the last 3 years. At FY26 sales of ₹876 Cr each day of that cycle holds about ₹2.4 Cr, so roughly ₹1,006 Cr sits inside the business at any moment.
FY26: debtors at 140 days, inventory at 399 days — roughly 13.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 419 days, tighter than FY21's 423.
The full loop: cash goes out to suppliers and production on day 0; stock waits 399 days to sell; customers pay about 140 days after that; and suppliers themselves are paid at 119 days — netting out to the 419-day cycle.
In money terms: at FY26 sales of ₹876 Cr, each day of the cycle holds about ₹2.4 Cr — so the 419-day loop keeps roughly ₹1,006 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹283 Cr over the last 3 fiscal years against ₹90.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹34.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
MTAR Technologies Ltd earns a ROCE of 15% in FY26. That is up from a trough of −7% in FY17. Return on invested capital clears the cost of that capital by +2.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 10.7% net margin on 0.50× asset turns.
FY26 ROCE is 15%, recovered from a FY17 trough of −7% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 10.7% net margin × 0.50× asset turns × 2.12× balance-sheet leverage ≈ 11.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 14.9% − 12.0% = a +2.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
MTAR Technologies Ltd carries total debt of ₹377 Cr against shareholder equity of ₹823 Cr as of Mar 26, a debt-to-equity of 0.46. On the annual view that ratio went from 0.18 in FY22 to 0.46 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹377 Cr against shareholder equity of ₹823 Cr — a debt-to-equity of 0.46. On the annual view, debt-to-equity went from 0.18 (FY22) to 0.46 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 17.1 points of MTAR Technologies Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 24.8% of the company. Promoters moved −7.1 points over the same window, to 29.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +17.1 points over 8 quarters to 24.8%; Promoters: −7.1 points over 8 quarters to 29.4%; Domestic institutions: +6.4 points over 8 quarters to 22.4%.
Why the register moved: foreign institutions drove it (+17.1 points), absorbed on the other side by promoters (−7.1 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
MTAR Technologies Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Sigma Advanced System LtdSIGMAADV | 72.6/100Favorable setup93% evidence | LEADER | 24.0/35 Revenue 100% · PAT 100% · OPM change -12 pp 83% evidence | 16.6/25 ROCE 60.8% · OPM 17% 95% evidence | 12.0/20 P/E 42.6× · PEG 2.35 100% evidence | 20.0/20 RS sector 105.2% · RS bench 142.5% · 1Y 494.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 16.6 + 12 + 20 = 72.6 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Sika Interplant Systems LtdSIKA | 72.6/100Favorable setup90% evidence | TURNING | 28.4/35 Revenue 43% · PAT 38.1% · OPM change 7.9 pp 88% evidence | 21.9/25 ROCE 34.6% · OPM 25.2% 100% evidence | 12.9/20 P/E 67.4× · PEG 1.01 100% evidence | 9.4/20 RS sector -10.2% · RS bench 6% · 1Y -1.7%3 of 7 weeks ahead 70% evidence |
| Exact sum: 28.4 + 21.9 + 12.9 + 9.4 = 72.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Astra Microwave Products LtdASTRAMICRO | 70.5/100Favorable setup96% evidence | LEADER | 21.0/35 Revenue 10.6% · PAT 27% · OPM change 4 pp 88% evidence | 19.4/25 ROCE 20.2% · OPM 33% 100% evidence | 10.8/20 P/E 91.6× · PEG 1.19 100% evidence | 19.3/20 RS sector 30.4% · RS bench 61.4% · 1Y 90.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 19.4 + 10.8 + 19.3 = 70.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Paras Defence and Space Technologies LtdPARAS | 66.4/100Favorable setup78% evidence | LEADER | 21.8/35 Revenue 30.4% · PAT 43.5% · OPM change -1 pp 83% evidence | 16.8/25 ROCE 16.9% · OPM 25% 76% evidence | 9.2/20 P/E 118× · PEG — 50% evidence | 18.6/20 RS sector 27.1% · RS bench 57.1% · 1Y 60.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 16.8 + 9.2 + 18.6 = 66.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5MTAR Technologies Ltdthis pageMTARTECH | 63.2/100Mixed-positive evidence90% evidence | FADING | 30.7/35 Revenue 53.5% · PAT 100% · OPM change 6 pp 100% evidence | 13.9/25 ROCE 15.1% · OPM 24% 100% evidence | 6.3/20 P/E 129× · PEG — 50% evidence | 12.3/20 RS sector 21.9% · RS bench 44.7% · 1Y 280.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 30.7 + 13.9 + 6.3 + 12.3 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Apollo Micro Systems LtdAPOLLO | 59.9/100Mixed-positive evidence96% evidence | LEADER | 21.9/35 Revenue 60.9% · PAT 92.9% · OPM change 1 pp 88% evidence | 14.2/25 ROCE 14.5% · OPM 23% 100% evidence | 7.1/20 P/E 128× · PEG 1.6 100% evidence | 16.7/20 RS sector 6.5% · RS bench 32% · 1Y 126.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 14.2 + 7.1 + 16.7 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Vinyas Innovative Technologies LtdVINYAS | 59.3/100Thin evidence · provisional57% evidence | TURNING | 21.7/35 Revenue 65% · PAT 100% · OPM change 3 pp 48% evidence | 18.5/25 ROCE 21.4% · OPM 13% 95% evidence | 10.9/20 P/E 51.1× · PEG — 15% evidence | 8.2/20 RS sector -17.5% · RS bench 6% · 1Y -6.9%10 of 11 weeks ahead 70% evidence |
| Exact sum: 21.7 + 18.5 + 10.9 + 8.2 = 59.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Data Patterns (India) LtdDATAPATTNS | 58.1/100Mixed-positive evidence100% evidence | FADING | 21.5/35 Revenue 33.9% · PAT 24.2% · OPM change -5 pp 100% evidence | 18.6/25 ROCE 21.9% · OPM 27% 100% evidence | 5.0/20 P/E 88.7× · PEG 3.94 100% evidence | 13.0/20 RS sector 5% · RS bench 30.1% · 1Y 59.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 18.6 + 5 + 13 = 58.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 9Azad Engineering LtdAZAD | 57.4/100Mixed-positive evidence89% evidence | FADING | 24.5/35 Revenue 32.2% · PAT 54% · OPM change 2 pp 88% evidence | 12.9/25 ROCE 11.9% · OPM 38% 100% evidence | 8.0/20 P/E 111× · PEG 2.29 65% evidence | 12.0/20 RS sector 1.6% · RS bench 27% · 1Y 47.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 12.9 + 8 + 12 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Ideaforge Technology LtdIDEAFORGE | 57.1/100Mixed-positive evidence68% evidence | LEADER | 24.6/35 Revenue 41% · PAT 71.4% · OPM change 152 pp 65% evidence | 4.6/25 ROCE -2.8% · OPM 44% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 17.9/20 RS sector 25.6% · RS bench 53.6% · 1Y 85.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 4.6 + 10 + 17.9 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Hindustan Aeronautics LtdHAL | 56.2/100Mixed-positive evidence96% evidence | BREAKING OUT | 11.0/35 Revenue 6.8% · PAT 9% · OPM change -3 pp 88% evidence | 21.1/25 ROCE 32% · OPM 36% 100% evidence | 15.2/20 P/E 34.1× · PEG 1.18 100% evidence | 8.9/20 RS sector -18.6% · RS bench 4% · 1Y 2.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11 + 21.1 + 15.2 + 8.9 = 56.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Rossell Techsys LtdROSSTECH | 54.1/100Mixed-positive evidence83% evidence | FADING | 29.0/35 Revenue 82.9% · PAT 68.8% · OPM change 1.8 pp 100% evidence | 7.4/25 ROCE 11.5% · OPM 14.4% 100% evidence | 9.0/20 P/E 136× · PEG — 15% evidence | 8.7/20 RS sector -3.2% · RS bench 20.7% · 1Y 64.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 7.4 + 9 + 8.7 = 54.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Jaykay Enterprises LtdJAYKAY | 49.0/100Mixed-negative evidence62% evidence | ASLEEP | 25.8/35 Revenue 100% · PAT 100% · OPM change 34 pp 62% evidence | 6.8/25 ROCE 8.2% · OPM -10% 95% evidence | 11.5/20 P/E 32.6× · PEG — 15% evidence | 4.9/20 RS sector -20.9% · RS bench -6.2% · 1Y 20.6%6 of 10 weeks ahead 70% evidence |
| Exact sum: 25.8 + 6.8 + 11.5 + 4.9 = 49 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -20.9% and the one-year return is 20.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 14Mishra Dhatu Nigam LtdMIDHANI | 45.7/100Mixed-negative evidence96% evidence | FADING | 16.3/35 Revenue 12.6% · PAT 18.9% · OPM change -2 pp 88% evidence | 13.7/25 ROCE 11.3% · OPM 21% 100% evidence | 7.4/20 P/E 56.4× · PEG 5.62 100% evidence | 8.3/20 RS sector -16.9% · RS bench 5.1% · 1Y -2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 13.7 + 7.4 + 8.3 = 45.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Dynamatic Technologies LtdDYNAMATECH | 43.8/100Mixed-negative evidence89% evidence | FADING | 16.2/35 Revenue 15.5% · PAT -23.3% · OPM change 1 pp 88% evidence | 10.2/25 ROCE 10% · OPM 11% 100% evidence | 10.3/20 P/E 140× · PEG 1.42 65% evidence | 7.1/20 RS sector -12.3% · RS bench 10.4% · 1Y 47.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 10.2 + 10.3 + 7.1 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Zen Technologies LtdZENTEC | 41.9/100Mixed-negative evidence69% evidence | ASLEEP | 5.0/35 Revenue -23.4% · PAT -27.8% · OPM change -14 pp 95% evidence | 16.6/25 ROCE 16.2% · OPM 27% 76% evidence | 10.5/20 P/E 80.7× · PEG — 15% evidence | 9.8/20 RS sector -6.5% · RS bench 6.5% · 1Y -8.7%8 of 10 weeks ahead 70% evidence |
| Exact sum: 5 + 16.6 + 10.5 + 9.8 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Bharat Electronics LtdBEL | 41.7/100Mixed-negative evidence100% evidence | ASLEEP | 14.0/35 Revenue 19.8% · PAT 11.8% · OPM change -3 pp 100% evidence | 18.6/25 ROCE 36.5% · OPM 25% 100% evidence | 7.3/20 P/E 46.1× · PEG 3.54 100% evidence | 1.8/20 RS sector -28% · RS bench -8% · 1Y -1.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 18.6 + 7.3 + 1.8 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Aequs LtdAEQUS | 36.4/100Thin evidence · provisional51% evidence | BREAKING OUT | 15.1/35 Revenue 44.3% · PAT — · OPM change -7.3 pp 74% evidence | 1.3/25 ROCE 1.6% · OPM 3.7% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 15.1 + 1.3 + 10 + 10 = 36.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Avantel LtdAVANTEL | 35.7/100Mixed-negative evidence77% evidence | TURNING | 10.1/35 Revenue -3.2% · PAT -67.2% · OPM change 4.6 pp 100% evidence | 9.2/25 ROCE 9.6% · OPM 24.8% 100% evidence | 8.7/20 P/E 251× · PEG — 15% evidence | 7.7/20 RS sector -11.9% · RS bench 0.1% · 1Y 19%8 of 11 weeks ahead 70% evidence |
| Exact sum: 10.1 + 9.2 + 8.7 + 7.7 = 35.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20AXISCADES Technologies LtdAXISCADES | 35.4/100Mixed-negative evidence96% evidence | ASLEEP | 15.4/35 Revenue 12.4% · PAT -4.3% · OPM change -1.7 pp 88% evidence | 12.3/25 ROCE 15.3% · OPM 12.3% 100% evidence | 4.9/20 P/E 83.6× · PEG 3.04 100% evidence | 2.8/20 RS sector -21.3% · RS bench -1.3% · 1Y 13.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 15.4 + 12.3 + 4.9 + 2.8 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21NIBE LtdNIBE | 32.4/100Adverse evidence65% evidence | TURNING | 9.6/35 Revenue -6.7% · PAT -80% · OPM change 3 pp 83% evidence | 7.6/25 ROCE 4.8% · OPM 20% 76% evidence | 8.5/20 P/E 380× · PEG — 15% evidence | 6.7/20 RS sector -29.8% · RS bench 11.1% · 1Y -17%11 of 11 weeks ahead 70% evidence |
| Exact sum: 9.6 + 7.6 + 8.5 + 6.7 = 32.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Bharat Dynamics LtdBDL | 29.4/100Adverse evidence83% evidence | ASLEEP | 7.6/35 Revenue -27% · PAT -23.6% · OPM change -5 pp 88% evidence | 12.9/25 ROCE 13.8% · OPM 12% 100% evidence | 5.0/20 P/E 109× · PEG 4.44 65% evidence | 3.9/20 RS sector -22.4% · RS bench -11.8% · 1Y -24.4%2 of 10 weeks ahead 70% evidence |
| Exact sum: 7.6 + 12.9 + 5 + 3.9 = 29.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23BEML LtdBEML | 26.3/100Adverse evidence90% evidence | ASLEEP | 6.5/35 Revenue 8.1% · PAT -51.5% · OPM change -11 pp 88% evidence | 5.3/25 ROCE 7.7% · OPM 15% 100% evidence | 9.5/20 P/E 103× · PEG 1.18 100% evidence | 5.0/20 RS sector -19.9% · RS bench -6.2% · 1Y -15.6%5 of 10 weeks ahead 70% evidence |
| Exact sum: 6.5 + 5.3 + 9.5 + 5 = 26.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24DCX Systems LtdDCXINDIA | 25.1/100Adverse evidence67% evidence | ASLEEP | 8.2/35 Revenue -31.4% · PAT -80% · OPM change -2 pp 83% evidence | 3.4/25 ROCE 0.9% · OPM -0.2% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -27% · RS bench -12.4% · 1Y -32%5 of 10 weeks ahead 70% evidence |
| Exact sum: 8.2 + 3.4 + 10 + 3.5 = 25.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is MTAR Technologies Ltd's share price today?
MTAR Technologies Ltd trades at ₹5,726, +301.0% over the past year. The company is valued at ₹17,613 Cr. The stock sits at 60% of its 52-week range of ₹1,798–₹8,375, +19.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 43 weeks in. — as of 31 July 2026.
What were MTAR Technologies Ltd's latest quarterly results?
MTAR Technologies Ltd reported revenue of ₹361 Cr and net profit of ₹50.0 Cr for the Jun 26 quarter. Revenue rose 129.9% and profit rose 354.5% year on year. Earnings per share were ₹16.33. The operating margin was 24.0%, 6.0 pp higher than a year earlier. — as of 31 July 2026.
What is MTAR Technologies Ltd's revenue?
MTAR Technologies Ltd reported revenue of ₹361 Cr in the Jun 26 quarter, +129.9% year on year. For the full FY26 fiscal year, revenue was ₹876 Cr (+29.6%). Over the last 10 years revenue compounded at 26.9% a year. — as of 31 July 2026.
What is MTAR Technologies Ltd's profit?
MTAR Technologies Ltd earned ₹50.0 Cr of net profit in the Jun 26 quarter, +354.5% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹94.0 Cr. The operating margin ran 24.0% in the latest quarter. — as of 31 July 2026.
What is MTAR Technologies Ltd's market cap?
MTAR Technologies Ltd's market capitalisation is ₹17,613 Cr at a share price of ₹5,726. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is MTAR Technologies Ltd's P/E ratio?
MTAR Technologies Ltd trades at a P/E of 129.0×, at the 74th percentile of its own 5-year range, against a long-run median of 91.7×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does MTAR Technologies Ltd pay a dividend?
Not in its latest year — MTAR Technologies Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 4 of its last 13 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is MTAR Technologies Ltd overvalued?
On its own history, MTAR Technologies Ltd looks expensive against its own history: its P/E of 129.0× sits at the 74th percentile of its 5-year range (long-run median 91.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is MTAR Technologies Ltd growing?
Yes — MTAR Technologies Ltd is growing: latest-quarter revenue +129.9% year on year, profit +354.5%, and the margin +6.0 pp at 24.0%. The earnings engine currently reads: improving — as of 31 July 2026.
How is MTAR Technologies Ltd performing?
MTAR Technologies Ltd is in a confirmed uptrend, 43 weeks in. Its latest quarter's revenue rose 129.9% and profit rose 354.5% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is MTAR Technologies Ltd in?
Improving — profit growth bottomed 7 quarters ago at −62.7% and has held its recovery at +121.7%, ROCE lifting at 16.9%. The read comes from the last 12 quarters of growth (revenue growth +53.6% latest, profit growth +121.7% latest, eps growth +125.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is MTAR Technologies Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 43 of stage 2), trading +19.0% versus its 200-day average and at 60% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is MTAR Technologies Ltd beating the market?
Not lately — on a trailing-13-week view MTAR Technologies Ltd is currently behind the NIFTY 500 (5 weeks and counting; last ahead the week of 2026-07-01), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.4 years the stock moved +491% against the NIFTY 500's +92% — ahead of the index over the full window. — as of 31 July 2026.
Will MTAR Technologies Ltd's share price go up?
This page publishes no price forecast for MTAR Technologies Ltd. What it measures instead: the share price is ₹5,726, the price is in a confirmed uptrend 43 weeks in. Its P/E of 129.0× sits at the 74th percentile of its own 5-year range. — as of 31 July 2026.
Who owns MTAR Technologies Ltd?
Promoters hold 29.4% of MTAR Technologies Ltd, foreign institutions 24.8%, domestic institutions 22.4% and the public 23.5% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 17.1 points over 8 quarters. — as of 31 July 2026.
Does MTAR Technologies Ltd have too much debt?
It is moderate — MTAR Technologies Ltd's debt-to-equity is 0.46, and operating profit covers the interest bill 6×. FY26 borrowings were ₹377 Cr against equity of ₹823 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is MTAR Technologies Ltd's capex?
MTAR Technologies Ltd spent ₹283 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹91.0 Cr, with ₹34.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is MTAR Technologies Ltd's cash flow?
MTAR Technologies Ltd generated ₹197 Cr of operating cash flow in FY26 and ₹106 Cr of free cash flow after ₹91.0 Cr of capital spending. Reported profit that year was ₹94.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is MTAR Technologies Ltd's profit real cash?
Yes — over the last 3 fiscal years, 175% of MTAR Technologies Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹197 Cr against reported profit of ₹94.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is MTAR Technologies Ltd in its business cycle?
MTAR Technologies Ltd's FY26 operating margin was 20.0%, against a 13-year band of −12.0%–34.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 24.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the MTAR Technologies Ltd story?
The sharpest disagreement: the price moved +301.0% in a year while annual EPS moved +77.8% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is MTAR Technologies Ltd a stock worth studying right now?
This is not investment advice. The machine read: MTAR Technologies Ltd's price has outrun its earnings. +301.0% in a year against EPS +77.8% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.